NASDAQ Listing Done, Oculis Eyes Phase III Readouts

Decent Cash Position After SPAC Merger

17 Mar 2023

Having taken the special purpose acquisition corporation route to list in the US, Switzerland's Oculis is waiting for some vital late-stage data, notably on OCS-01 for diabetic macular edema.

Drops — • Source: Shutterstock: ShutterDivision

Fresh from completing its merger with a special purpose acquisition corporation (SPAC), Oculis S.A. can once again focus on the clinical progress of its eye disease pipeline.

The Swiss biotech says it has completed enrolment for a Phase III trial evaluating OCS-01, a once-daily novel eye-drop formulation...